drugset / Trial / NCT02352831
Tosedostat With Capecitabine in Patients With Metastatic Pancreatic Adenocarcinoma
Non-randomizedSingle-groupOpen-labelTreatment
Summary
There are two parts to this study: the goal of the first part of the study is to find the best dose of tosedostat when given in combination with capecitabine. The goal of the second part of the study is to look at how participants respond to treatment with tosedostat and capecitabine.
Timeline
- Start
- 2015-08-31
- Primary completion
- 2017-10-20
- Completion
- 2018-10-19
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Capecitabine | Small molecule | 1000 mg/m2 | Oral |
| Subject | Tosedostat | Small molecule | 60 mg | Oral |
| Subject | Tosedostat | Small molecule | 120 mg | Oral |